Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Radius Health trading halted, volatility trading pause  15:58
03/16/20
03/16
15:58
03/16/20
15:58
RDUS

Radius Health

$12.66 /

-3.16 (-19.97%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Radius Health expects cash to fund operations for at least 12 months » 08:17
02/27/20
02/27
08:17
02/27/20
08:17
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

As of December 31, 2019,…

As of December 31, 2019, Radius had $161.5 million in cash, cash equivalents, restricted cash, and marketable securities. Based upon our cash, cash equivalents and marketable securities balance as of December 31, 2019 and funds available to us through our credit facilities, we believe that, prior to the consideration of potential proceeds from partnering and/or collaboration activities, we have sufficient capital to fund our development plans, U.S. commercial and other operational activities for at least twelve months from the date of this press release.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Radius Health expects to complete recruitment for EMERALD study in Q3 » 08:16
02/27/20
02/27
08:16
02/27/20
08:16
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

The EMERALD Phase 3 study…

The EMERALD Phase 3 study is currently enrolling patients in multiple countries and is on track to complete recruitment of 466 patients in the third quarter of 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Radius Health expects topline data from wearABLe Phase 3 study in 2H21 » 08:15
02/27/20
02/27
08:15
02/27/20
08:15
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

The wearABLe Phase 3…

The wearABLe Phase 3 study is open for enrollment at more than 60 clinical sites in the U.S., reflecting strong interest from investigators. The Company has implemented a revised enrollment plan, added more clinical sites in the U.S., and made progress filing regulatory submissions to expand sites outside the U.S. The screen failure rate which started higher than expected at the initiation of the study is improving, driven by higher screening success at targeted bone specialty sites. Radius expects to report top-line data from the study in the second half of 2021.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Radius Health expects topline data from ATOM Phase 3 study in 2H21 » 08:15
02/27/20
02/27
08:15
02/27/20
08:15
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

Radius expects to…

Radius expects to complete recruitment of the ATOM Phase 3 Study, which is assessing the efficacy and safety of abaloparatide-SC in male osteoporosis, this year and report top-line data in the second half of 2021.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Radius Health expects to achieve profitability over next three years » 08:14
02/27/20
02/27
08:14
02/27/20
08:14
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

Over the next three years…

Over the next three years Radius expects TYMLOS revenue to grow at a greater than 20% compound annual growth rate and the Company to achieve profitability.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Radius Health sees FY20 TYMLOS U.S. revenue $220M-$235M » 08:13
02/27/20
02/27
08:13
02/27/20
08:13
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

Revenue consensus…

Revenue consensus $246.17M. Sees cash burn below $80M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Radius Health reports Q4 EPS (54c), consensus (77c) » 07:38
02/27/20
02/27
07:38
02/27/20
07:38
RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

Reports Q4 revenue…

Reports Q4 revenue $55.66M, consensus $53.29M. "I am very pleased that TYMLOS exited 2019 with a December majority share of postmenopausal osteoporosis patients starting on anabolic therapy in the U.S. market. In 2020, we have three critical objectives: continue expanding our market share for TYMLOS, reach anabolic total market share leadership, and complete recruitment in our three pivotal Phase 3 studies," said Jesper Hoeiland, President and Chief Executive Officer of Radius.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
SVB Leerink to hold a conference » 04:55
02/27/20
02/27
04:55
02/27/20
04:55
ABBV

AbbVie

$88.40 /

-0.73 (-0.82%)

, BBIO

BridgeBio

$32.67 /

+0.72 (+2.25%)

, CYAD

Celyad

$9.78 /

-0.17 (-1.71%)

, DCPH

Deciphera

$54.35 /

+0.495 (+0.92%)

, FULC

Fulcrum Therapeutics

$18.50 /

+2.28 (+14.06%)

, GH

Guardant Health

$81.52 /

+5.75 (+7.59%)

, IMVT

Immunovant

$14.87 /

+0.015 (+0.10%)

, INGN

Inogen

$47.88 /

+5.92 (+14.11%)

, LMAT

LeMaitre

$29.53 /

-0.35 (-1.17%)

, NUAN

Nuance

$22.27 /

+0.17 (+0.77%)

, NVCN

Neovasc

$2.70 /

+0.04 (+1.50%)

, RARE

Ultragenyx

$55.71 /

+0.88 (+1.60%)

, QURE

uniQure

$53.57 /

-0.96 (-1.76%)

, SELB

Selecta Biosciences

$4.21 /

+0.215 (+5.38%)

, VCEL

Vericel

$15.06 /

-1.645 (-9.85%)

, RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

, PODD

Insulet

$180.00 /

-17.03 (-8.64%)

, RDHL

RedHill Biopharma

$4.68 /

+0.12 (+2.63%)

, TCRR

TCR2 Therapeutics

$13.67 /

+0.36 (+2.70%)

, ORGO

Organogenesis

$4.23 /

-0.14 (-3.20%)

, OSMT

Osmotica Pharmaceuticals

$5.45 /

+0.32 (+6.24%)

, MLND

Millendo Therapeutics

$8.75 /

+0.08 (+0.92%)

, ITCI

Intra-Cellular

$22.24 /

-0.79 (-3.43%)

, IFRX

InflaRx

$4.84 /

+0.69 (+16.63%)

, STSA

Satsuma Pharmaceuticals

$26.10 /

-0.22 (-0.84%)

, MIRM

Mirum Pharmaceuticals

$16.53 /

-0.81 (-4.67%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
SVB Leerink to hold a conference » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
ABBV

AbbVie

$89.13 /

-4.01 (-4.31%)

, BBIO

BridgeBio

$31.95 /

-1.3 (-3.91%)

, CYAD

Celyad

$9.95 /

+ (+0.00%)

, DCPH

Deciphera

$53.86 /

+0.055 (+0.10%)

, FULC

Fulcrum Therapeutics

$16.22 /

-0.09 (-0.55%)

, GH

Guardant Health

$75.77 /

-8.32 (-9.89%)

, IMVT

Immunovant

$14.86 /

+0.055 (+0.37%)

, INGN

Inogen

$41.96 /

-1.54 (-3.54%)

, LMAT

LeMaitre

$29.88 /

-0.22 (-0.73%)

, NUAN

Nuance

$22.10 /

-0.73 (-3.20%)

, NVCN

Neovasc

$2.66 /

-0.21 (-7.32%)

, RARE

Ultragenyx

$54.83 /

-2.26 (-3.96%)

, QURE

uniQure

$54.53 /

-3.85 (-6.59%)

, SELB

Selecta Biosciences

$4.00 /

-0.225 (-5.33%)

, VCEL

Vericel

$16.71 /

-2.22 (-11.73%)

, RDUS

Radius Health

$17.93 /

-1.05 (-5.53%)

, PODD

Insulet

$197.03 /

-10.46 (-5.04%)

, RDHL

RedHill Biopharma

$4.56 /

-0.15 (-3.18%)

, TCRR

TCR2 Therapeutics

$13.31 /

-0.37 (-2.70%)

, ORGO

Organogenesis

$4.37 /

-0.13 (-2.89%)

, OSMT

Osmotica Pharmaceuticals

$5.13 /

-0.46 (-8.23%)

, MLND

Millendo Therapeutics

$8.67 /

-0.8 (-8.45%)

, ITCI

Intra-Cellular

$23.03 /

-0.02 (-0.09%)

, IFRX

InflaRx

$4.15 /

-0.1 (-2.35%)

, STSA

Satsuma Pharmaceuticals

$26.32 /

-0.22 (-0.83%)

, MIRM

Mirum Pharmaceuticals

$17.34 /

-1 (-5.45%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.